New drug duo aims to save bladders in HER2-positive cancer patients
NCT ID NCT07151560
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests two drugs—disitamab vedotin and toripalimab—as a way to treat HER2-positive muscle-invasive bladder cancer without removing the bladder. About 60 adults with locally advanced cancer will receive different cycles of the combination. The main goal is to see how many patients remain cancer-free with their bladder intact after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disitamab vedotin and toripalimab
What this could lead to
If successful, this combination could offer a way to treat HER2-positive bladder cancer without removing the bladder, improving quality of life.
What could go wrong
This is an early phase 2 trial with only 60 people, so results are uncertain. The drugs may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.